Life’s Essential 8 and its role in cardiovascular health: evolution, evidence, and future directions

Introduction: Cardiovascular disease (CVD) remains the leading global cause of mortality. To improve prevention, the American Heart Association introduced Life’s Simple 7 (LS7) in 2010 and updated it to Life’s Essential 8 (LE8) in 2022. This review summarizes the development, scientific rationale, predictive validity, and clinical applications of LE8 across diverse populations. Areas covered: A comprehensive search of PubMed, EMBASE, and Scopus through December 2025 identified studies evaluating LS7 and LE8 in U.S. and international cohorts. Evidence from prospective studies, registries, and validation analyses was synthesized to assess prognostic performance. LE8 includes diet, physical activity, nicotine exposure, sleep health, body mass index, blood lipids, blood glucose, and blood pressure, each scored on a 0–100 scale. Higher LE8 scores consistently correlate with lower risks of cardiovascular disease, stroke, heart failure, cognitive decline, chronic kidney disease, and all-cause mortality. Findings from NHANES, ARIC, CARDIA, and REGARDS demonstrate strong prognostic validity, while international studies support reproducibility. Expert opinion: LE8 provides a practical framework for cardiovascular health assessment, risk communication, and prevention. Broader implementation may improve population health, although challenges remain, including reliance on self-reported measures and limited integration of psychosocial and environmental determinants of health.